Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019)

Award Number: R01FD006849
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2020
PERIOD OF PERFORMANCE END DATE: 06/30/2023

Group Awards By:

View Award Description

A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019) - Project Summary Stargardt disease (STGD) is a rare, inherited, degenerative disease of the retina, reducing visual acuity to 20/200 or worse beginning in the first 3 decades of life. Calculated estimates indicate STGD affects roughly 41,119 patients in the US, making it the most common hereditary macular dystrophy. There are currently no approved treatments for STGD anywhere worldwide. STGD is characterized by an excessive build-up of lipofuscin at the level of the retinal pigment epithelium (RPE). The visual cycle isomerohydrolase, RPE65, plays a key role in this chemical pathway. Inhibition of RPE65 reduces accumulation of lipofuscin and its component bisretinoids; hence, it may slow the progression of STGD. Acucela, Inc. (Acucela) has developed emixustat hydrochloride (emixustat), an orally administered inhibitor that targets RPE65. Acucela is now conducting the SeaSTAR study, a phase 3 multicenter, randomized, double-masked study to compare the efficacy and safety of emixustat with placebo for the treatment of macular atrophy secondary to STGD. The hypothesis is that emixustat slows the progression of STGD by reducing retinal pathology caused by the accumulation of lipofuscin. The data obtained in the proposed study will significantly advance the STGD field in two ways. If emixustat demonstrates efficacy by reducing the rate of disease progression, it would present a major step forward in developing the first available treatment for STGD patients. Additionally, the SeaSTAR study will contribute substantially to the understanding of the natural history of STGD due to the large number of patients on placebo. The most significant obstacle in the field of inherited retinal diseases such as STGD has been an inadequate understanding of the natural history of these diseases. While recent advances have provided important data on certain aspects of the natural history of the disease, information in particular on additional functional and structural endpoints as well as quality-of-life measures is still lacking. The SeaSTAR study will gather data on these measures to fill this knowledge gap. Confirming the hypothesis that emixustat reduces the accumulation of lipofuscin would provide invaluable proof-of-concept that RPE65 is a valid therapeutic target for further drug development. Additionally, both the US and European governmental drug approval agencies have agreed that positive results will be evidence of safety and efficacy that can be used for marketing approval of emixustat as the first approved treatment available for STGD. The primary efficacy endpoint will be the mean rate of change in mm2/year from baseline in the total area of macular atrophy lesion(s) in the study eye. Secondary endpoints include, among several, safety and tolerability evaluations, mean change from baseline in retinal sensitivity, and quality-of-life measurements such as the Functional Reading Independence Index. Exploratory endpoints are mean change from baseline in extent of abnormal near-infrared fundus autofluorescence and the relationship between pharmacokinetic exposure of emixustat and efficacy response. In summary, the results of this study will at minimum expand the field of knowledge of the natural history of STGD and if fully successful provide the first evidence of a treatment effect in this debilitating, blinding disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	ACUCELA INC.	600 UNIVERSITY ST	SEATTLE	WA	98101	KING	USA	Food and Drug Administration Research	000	3	4/29/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $545,000 )
2022	2022	ACUCELA INC.	600 UNIVERSITY ST STE 2900	SEATTLE	WA	98101	KING	USA	Food and Drug Administration Research	000	3	5/20/2022	NON-COMPETING CONTINUATION	$545,000
														Subtotal = $545,000

Issue Date FY: 2021 ( Subtotal = $545,000 )
2021	2021	ACUCELA INC.	600 UNIVERSITY ST STE 2900	SEATTLE	WA	98101	KING	USA	Food and Drug Administration Research	000	2	6/30/2021	NON-COMPETING CONTINUATION	$545,000
														Subtotal = $545,000

Issue Date FY: 2020 ( Subtotal = $543,917 )
2020	2020	ACUCELA INC.	818 STEWART ST STE 1110	SEATTLE	WA	98101	KING	USA	Food and Drug Administration Research	000	1	8/20/2020	NEW	$543,917
														Subtotal = $543,917

Grand Total All Awards = $1,633,917

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019)

Award Number: R01FD006849

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2020

PERIOD OF PERFORMANCE END DATE: 06/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer